SCHEMBL7674985

SCHEMBL7674985

CC(=O)Oc1ccnc(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
CYP3A4 P08684 2/20 0.47
ACHE P22303 2/20 0.46
UHRF1 Q96T88 1/20 0.43
KDM4E B2RXH2 6/20 0.43
GLA P06280 4/20 0.41
GAA P10253 3/20 0.41
ALDH1A1 P00352 2/20 0.41
F2 P00734 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DYRK1A Q13627 1/20 0.41
ABCB11 O95342 1/20 0.41
ESR1 P03372 1/20 0.41
ADRA2A P08913 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
PDE4A P27815 1/20 0.41
ADRA1A P35348 1/20 0.41
OPRK1 P41145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10529996 0.98 LMNA (0.50) LMNACYP3A4ACHEUHRF1KDM4E
SCHEMBL15880687 0.83 KMT2A (0.52) UHRF1KDM4EDYRK1APORCN
SCHEMBL17669635 0.82 CCR1 (0.55) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL9670309 0.81 LMNA (0.47) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL27748129 0.80 ACHE (0.50) ACHEUHRF1KDM4EGLAGAA
SCHEMBL25348842 0.79 LMNA (0.46) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL27575926 0.79 NOS3 (0.58) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL2860423 0.79 LMNA (0.46) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL28922557 0.78 LMNA (0.49) LMNACYP3A4ACHEKDM4EGLA
SCHEMBL241030 0.78 PORCN (0.42) LMNAACHEUHRF1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023006013-A1 NOVEL PARP7 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2023-02-02 WO disclosed
CN-103748087-A Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof DAINIPPON SUMITOMO PHARMA CO 2014-04-23 CN disclosed
CN-102648198-A Pyridine derivatives as S1P1/EDG1 receptor modulators ACTELION PHARMACEUTICALS LTD 2012-08-22 CN disclosed
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases BISHOP W ROBERT (US) 2002-06-06 US disclosed
US-6242458-B1 INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN SCHERING CORPORATION 2001-06-05 US disclosed
US-5700806-A FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS SCHERING CORPORATION (US) 1997-12-23 US disclosed
US-4797411-A ANTITUMOR AGENTS FARMITALIA CARLO ERBA S.P.A. (IT) 1989-01-10 US disclosed
EP-0253681-A2 Cycloalkyl-substituted 4-pyridyl derivatives and process for their preparation FARMITALIA CARLO ERBA S.r.l. (IT) 1988-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068742-A1 Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases RASGRP1, CCNA1, CCNA2 LMNA 3835/4885CYP3A4 3752/4885ACHE 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.